Boehringer Ingelheim is accepting proposals for the 2018 Advancement in Equine Research Awards for Equine Respiratory Disease Research.
“Boehringer Ingelheim is a global leader in equine health that is committed to supporting leading equine research,” says Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer Ingelheim. “Past Advancement in Equine Research Award recipients have uncovered scientific breakthroughs that contribute significantly to equine health. Now supporting the Awards for the eighth year, we’re looking for proposals from both public and private researchers studying equine infectious respiratory disease and equine asthma syndrome.”
Veterinarians, diagnosticians, public and private researchers in the United States, Canada and Mexico are eligible to submit proposals for research programs that help advance the diagnosis, treatment and understanding of equine disease. Boehringer Ingelheim will present five separate $15,000 awards focused on two specific disease topics.Proposals must address one of the two following focus areas for consideration:
- Equine Infectious Respiratory Disease
- Equine Asthma Syndrome
Proposals must be submitted by September 15, 2018, and will be reviewed by an independent review board that consists of renowned equine industry professionals, including practicing veterinarians and researchers. The board will peer review and select proposals based on probability of successfully completing the project, potential for impact to the equine industry, originality and scientific quality. The awards will be announced at the 64th annual American Association of Equine Practitioners Convention December 1-5, 2018.
To participate in the awards program, submit a proposal, cover letter, curriculum vitae and two letters of recommendation by September 15, 2018, to:
Boehringer Ingelheim Vetmedica, Inc.
Attn: Dr. Steve Grubbs
The 2018 Advancement in Equine Research Awards
3902 Gene Field Rd.
St. Joseph, MO 64506
The Boehringer Ingelheim Advancement in Equine Research Awards were launched in 2011 to support veterinary research that results in practical applications for or insights into important equine infectious diseases and improves the quality of life for all horses. More than $455,000 has been awarded to date for research into these diseases, which include equine influenza, equine rhinitis virus, coronavirus and pigeon fever.
For more information and complete submission instructions, please visit www.equinediseaseresearch.com.
About Boehringer Ingelheim Animal Health
As the second-largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.